Safety, Tolerability, Efficacy of MTP-131 for Treatment of Mitochondrial Disease in Subjects From the MMPOWER Study

NCT02805790 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Mitochondrial Disease

Interventions

DRUG: Elamipretide
DRUG: Placebo

Sponsor

Stealth BioTherapeutics Inc.